Location of Disease on Imaging may Predict Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography.

Location of Disease on Imaging may Predict Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography.

Radiat Prot Dosimetry. 2017 Apr 11;:1-5

Authors: Choi MH, Jung SE, Yoon SB, Lee IS, Byun JY

Abstract
Endoscopic retrograde cholangiopancreatography (ERCP) is performed for various diseases. The aim of this study is to evaluate the difference of dose-area product (DAP) during the ERCP procedures according to location of the lesion. We performed a retrospective study of consecutive 217 therapeutic ERCP examinations performed between November 2014 and April 2015 at a tertiary care center. ERCP procedures divided into two groups according to location of the lesion identified on imaging: lesions in the common hepatic duct (CHD) or the common bile duct (CBD) and lesions in the hepatic hilum or the intrahepatic duct (IHD). The mean DAP of the hilum-IHD group (48.7 Gy cm2) was significantly higher than that of the CBD-CHD group (34.9 Gy cm2) (P = 0.003). Radiation exposure during ERCP was significantly different according to location of bile duct lesion.

PMID: 28402484 [PubMed - as supplied by publisher]

http://ift.tt/2pwKKvQ